当前，阿维塔科技正处于产品推广、市场拓展、销量提升，以及港股IPO的关键时期。公开数据显示， 2025年，阿维塔科技全年累计销量突破12万辆。 （文章来源：每日经济新闻） 1月29日，《每日经济新闻》记者从阿维塔科技方面获悉，孙百功任阿维塔科技副总裁，负责市场推 广、产品操盘、营销体系建设等工作。 公开资料显示，2005年，孙百功入职华为，曾任荣耀中东非洲总裁等职位。2024年1月，孙百功担任理 想汽车副总裁。 ...

Group 1 - The Hong Kong IPO market remains active in January 2026, with 12 companies listed and total fundraising reaching HKD 34.747 billion, a year-on-year increase of 480.87% [1] - There are over 300 companies in the queue for listing on the Hong Kong Stock Exchange, providing ample resources for sustained market activity [1] Group 2 - The companies listed at the beginning of 2026 are primarily focused on hard technology sectors such as semiconductors, AI, and biomedicine, including domestic GPU company Birun Technology and AI model company Zhipu [2] - The participation rate of international long-term capital in Hong Kong IPO projects has surged from approximately 10%-15% in early 2024 to 85%-90% currently, with significant involvement from Middle Eastern sovereign wealth funds and European family offices [2] - Market institutions predict that the fundraising scale for Hong Kong IPOs in 2026 may exceed HKD 300 billion, with a market characteristic of "large at both ends and differentiated in the middle," favoring large projects and industry leaders for funding support [2]

Group 1: Company Overview - Dazhu CNC Technology Co., Ltd. is a leading provider of PCB production equipment solutions in China, focusing on R&D, production, and sales of specialized equipment for PCB manufacturing. The company operates in sectors such as server and data storage, automotive electronics, mobile phones, computers, and consumer electronics. According to Zhaoshang Consulting, it holds a 10.1% market share in the PCB production equipment manufacturing sector in China as of 2024 [3] - Muyuan Foods Co., Ltd. is a technology-driven leader in the pork industry, established in 1992. The company operates through two main business segments: (i) pig farming, which includes the breeding and sale of commercial pigs, piglets, and breeding pigs, and (ii) meat processing, which involves the slaughtering and sale of pork products [9] - Distinct Healthcare Holdings Limited focuses on providing high-end medical services, targeting affluent consumers who prefer personalized healthcare. The company operates 19 medical institutions across major cities in China and has clinics in Singapore and Malaysia [15][16] Group 2: IPO Details - Dazhu CNC plans to offer 50.45 million shares globally, with 10% allocated for Hong Kong and 90% for international sales. The maximum offer price is set at HKD 95.8 per share, with an expected trading start date of February 6, 2026 [1] - Muyuan Foods intends to issue 274 million shares, with a maximum offer price of HKD 39.00 per share. The shares are also expected to start trading on February 6, 2026 [7] - Distinct Healthcare plans to offer 4.75 million shares, with a price range of HKD 57.7 to 66.6 per share, and is expected to begin trading on February 6, 2026 [13] Group 3: Financial Performance - Dazhu CNC's revenue for the years 2022, 2023, and 2024 was RMB 2.786 billion, RMB 1.634 billion, and RMB 3.343 billion, respectively. The net profit for the same years was RMB 432 million, RMB 136 million, and RMB 300 million [6] - Muyuan Foods reported revenues of RMB 124.826 billion, RMB 110.861 billion, and RMB 137.947 billion for the years 2022, 2023, and 2024, respectively. The net profit for these years was RMB 14.933 billion, a loss of RMB 4.168 billion, and RMB 18.925 billion [12] - Distinct Healthcare's revenue for 2022, 2023, and 2024 was RMB 473 million, RMB 690 million, and RMB 959 million, respectively. The company experienced a net loss of RMB 222 million in 2022, which increased to RMB 353 million in 2023, but achieved a net profit of RMB 80 million in 2024 [18]

总体而言，高盛集团首席执行官苏德巍(David Solomon)公开表示，展望2026年，港股IPO市场有望迎来 强劲复苏，并将成为"非常好的一年"。高盛方面认为，若宏观环境保持相对稳定、市场流动性持续改 善，香港2026年在IPO数量和融资规模方面均有望实现明显回升。 值得注意的是，港股IPO热潮涌动之下，业务量的激增也导致"赶工"现象频频出现。部分内地企业为启 动境内的监管审批流程，出现了向港交所提交不完整的"占位"申请、上市申请文件质量低劣且审查不 足、保荐人对监管问询反馈滞后且不到位、发售流程执行混乱等问题，引起了市场关注。 港交所集团行政总裁陈翊庭在瑞士达沃斯世界经济论坛期间接受媒体采访时表示，近期港股IPO出现质 量不佳的原因，是IPO数量突然上升带来的兴奋情绪，导致资源与协作面临压力。IPO质量绝对"不能妥 协"，这是维护市场信任的基础，须确保每宗上市申请的质量及尽职调查到位。近期已就部分质量欠佳 的IPO申请发出的警示，是在提醒专业人士速度必须与质量并行。 （上接1版） 上述A股公司普遍在公告中表示，赴港上市是为了推动公司全球化战略深入实施、拓宽融资渠道、加速 发展海外业务。在出海趋势下，港股 ...

2025年港股IPO行情火热，全年IPO数量达117家，募资金额达2863.3亿港元，一举位居全球IPO募资榜 首位置。步入2026年，港股IPO依旧火热，超350家企业排队等待。 然而，日前关于港股IPO收紧的传闻却在市场上流传开来。该传闻指出，有券商收到指导，要求拟赴港 上市的AH企业需满足300亿元的市值门槛。 针对上述传闻，湾财社记者向多位券商人士核实，均表示"没听说过这个说法"。不过，有券商人士强 调，其所在公司近期对于赴港上市的项目门槛确有提升，对于不满足市值要求的，需论证行业龙头属 性。 聚焦市场传闻背后，湾财社注意到，港股上市规则调整带来了政策红利，港股IPO的赚钱效应则进一步 抬升投资者热情。 AH上市门槛提升至300亿元？ 2025年以来，随着政策放宽和市场情绪回暖，港股IPO热度走高，2025年全年IPO数量达117家，募资金 额达2863.3亿港元，同比增长224.8%；同时，再融资的规模也同步上升至3263.7亿港元，同比增长 272.9%。此外，2025年AtoH项目共19个，占比达16.4%，为近10年来最高，且显著高于过往各年。 多项增长、新高数据之下，2025年成为了港交所2 ...

2025年港股IPO行情火热，全年IPO数量达117家，募资金额达2863.3亿港元，一举位居全球IPO募资榜首位置。步 入2026年，港股IPO依旧火热，超350家企业排队等待。 然而，日前关于港股IPO收紧的传闻却在市场上流传开来。该传闻指出，有券商收到指导，要求拟赴港上市的AH 企业需满足300亿元的市值门槛。 针对上述传闻，湾财社记者向多位券商人士核实，均表示"没听说过这个说法"。不过，有券商人士强调，其所在 公司近期对于赴港上市的项目门槛确有提升，对于不满足市值要求的，需论证行业龙头属性。 聚焦市场传闻背后，湾财社注意到，港股上市规则调整带来了政策红利，港股IPO的赚钱效应则进一步抬升投资 者热情。 AH上市门槛提升至300亿元？ 2025年以来，随着政策放宽和市场情绪回暖，港股IPO热度走高，2025年全年IPO数量达117家，募资金额达2863.3 亿港元，同比增长224.8%；同时，再融资的规模也同步上升至3263.7亿港元，同比增长272.9%。此外，2025年 AtoH项目共19个，占比达16.4%，为近10年来最高，且显著高于过往各年。 多项增长、新高数据之下，2025年成为了港交所20 ...

风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 陈达美股投资 来源：雪球 第一个将IPO比喻成抽血的人值一个诺贝尔经济文学奖，因为事实就是如此，如果一个市场的IPO抽血太狠，这个市场就是会倾向于不长个。 整个2025年港股市场IPO，117个新股上市，一共募资2867亿港币，折合368亿美元，创四年新高。许多文章与报道说2025年的港股全球IPO第一， 这是直接粘贴复制AI、不做事实核查的fake news，因为美股2025年全年IPO募资是在700亿美元以上；如果港股IPO是大盘鸡的话，那美股就是大 盘鹅。 但考虑到港股总体量大概6.4万亿美元，而美股是近70万亿，你做一下除法，新股募资/总市值，可得美股为10个bps，而港股高达57.5个。如果这可 以看成某个市场IPO的强度值的话，那这方面阿港显然冠绝环宇。 这就好比，你只有7只鹅，而隔壁老王家有70只；结果拔了一年鹅毛，一算，你拔下来的鹅毛至少是老王家的一半，等于以一敌五，此时求你家大 鹅的心理阴影面积。如果故意拔鹅罪能判刑，那你至少是个无期。也难怪2025年最后两个月，你家鹅被拔得陷入了重度抑郁之中，行情 ...

Core Viewpoint - The article discusses the increasing participation of bank wealth management subsidiaries in Hong Kong IPOs, highlighting their role as significant players in the market as it enters a new phase of intensive IPO activity from late 2025 to early 2026 [2][3]. Group 1: Bank Wealth Management Subsidiaries' Participation - Bank wealth management subsidiaries, such as ICBC Wealth Management and China Post Wealth Management, have been actively investing in Hong Kong IPOs, with ICBC participating in over 25 IPOs since 2025, achieving a weighted return of over 50% [3]. - China Post Wealth Management has invested 1.8 billion yuan in Hong Kong IPOs and participated in 150 private placements, focusing on new productivity sectors [4]. - Other subsidiaries like China Merchants Bank Wealth Management have also engaged in IPOs, successfully acquiring shares in companies like Innovation Industry [4]. Group 2: Investment Strategies and Product Offerings - Wealth management firms are embedding Hong Kong IPO investments into their product offerings, allowing individual investors to access these opportunities, with some products starting from as low as 1 yuan [5][6]. - ICBC Wealth Management has developed a "fixed income + Hong Kong IPO" strategy, combining deposits and high-grade bonds with selected IPO investments to enhance returns [5]. - China Post Wealth Management has introduced products that flexibly allocate between Hong Kong IPOs and domestic ETFs, aiming to capture the benefits of leading companies going public [6]. Group 3: Market Dynamics and Challenges - The influx of wealth management funds into Hong Kong IPOs is driven by a scarcity of quality fixed-income assets domestically, the strategic positioning in technology and biomedicine sectors, and the need for innovative product offerings [7]. - Experts predict that a significant amount of medium- to long-term deposits will mature in 2026, potentially impacting financial markets and asset allocation [7]. - Despite the opportunities, wealth management firms face challenges such as insufficient cross-border research capabilities, liquidity management issues, and the need for better investor education regarding the risks associated with IPO investments [9].

Group 1 - The rumor regarding a "300 billion market cap threshold for Hong Kong IPOs" has been confirmed as unfounded by multiple investment banking professionals, indicating that such a limit is impractical given the current market conditions [1] - There are currently 337 companies in the IPO queue, many of which have market caps below 300 billion, suggesting that imposing such a threshold could hinder financing for small and medium enterprises and negatively impact industry growth [1] Group 2 - The current IPO landscape in Hong Kong is characterized by the difficulty of issuance despite easier approval processes, with increasing pressure on companies as the number of listings rises [2] - Companies that are likely to attract interest in the Hong Kong market fall into two categories: innovative firms in biotechnology and specialized technology sectors, and traditional industry leaders with strong performance and profitability [3] - Predictions indicate that the IPO market will continue to heat up through 2026, with a focus on new economy sectors like AI and biomedicine, although the challenges of issuance will persist [3]

Core Viewpoint - The Hong Kong IPO market is experiencing a robust recovery in 2026, with a significant increase in both supply and demand, driven by enthusiasm from leading A-share companies to list in Hong Kong, including trends like spin-off listings and H-share returning to A-share markets [1][2]. Group 1: IPO Market Trends - As of January 27, 2026, 12 companies have listed on the Hong Kong Stock Exchange, with over 300 companies having submitted listing applications, marking a substantial increase compared to previous years [1]. - The number of active IPO applications from A-share companies has increased nearly fourfold in 2025 compared to 2024, with over 110 applicants from the A-share market [1][2]. - The quality and scale of A-share companies applying for Hong Kong listings have improved, with most companies having a market capitalization exceeding 10 billion yuan, such as 汇川技术 (over 200 billion yuan) and 德赛西威 (approximately 77 billion yuan) [2]. Group 2: Industry Distribution - The companies planning to list are primarily leaders in niche sectors, focusing on strategic emerging industries such as new energy, biomedicine, and advanced manufacturing [2]. - Notable companies in the new energy sector include 汇川技术, 正泰电器, and 鹏辉能源, while the biomedicine sector features leaders like 信立泰, 海特生物, and 仙乐健康 [2]. Group 3: Market Dynamics - The trend of spin-off listings has gained momentum, with over 10 A-share companies' subsidiaries listing in Hong Kong since 2025, and this trend is accelerating in 2026 [3]. - A dual listing trend is emerging, with several Hong Kong-listed companies initiating "return to A-share" plans, exploring new paths for "A+H" listings [4]. - The Hong Kong Stock Exchange has expanded its recognition of overseas exchanges, now including 20 foreign exchanges from 18 countries, enhancing the market's diversity [4]. Group 4: Market Outlook - UBS forecasts that the IPO financing scale in Hong Kong could exceed 300 billion HKD in 2026, with the number of new listings expected to reach between 150 and 200 [2]. - The Hong Kong IPO market is entering a positive cycle of supply and demand, with expectations for further growth in both the number and scale of IPOs in 2026 [4].